This Article Full Text Full Text (PDF) All Versions of this Article: 45/3/380    most recent 01.HYP.0000156746.25300.1cv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stokes, G. S. Articles by Barin, E. S. Search for Related Content PubMed PubMed Citation Articles by Stokes, G. S. Articles by Barin, E. S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure Hazardous Substances DB ISOSORBIDE DINITRATE Related Collections Clinical Studies Other Treatment

(Hypertension. 2005;45:380.)
© 2005 American Heart Association, Inc.

Original Articles

Long-Term Effectiveness of Extended-Release Nitrate for the Treatment of Systolic Hypertension

From Hypertension Unit, Royal North Shore Hospital, St Leonards, NSW, Australia.

Correspondence to G.S. Stokes, Hypertension Unit, Block 1B, Royal North Shore Hospital, St Leonards, NSW, 2065, Australia. E-mail gstokes{at}med.usyd.edu.au

Abstract

Isosorbide mononitrate (ISMN) is effective in the short-term for decreasing systolic blood pressure, pulse pressure, and pulse wave reflection in patients with systolic hypertension. To determine whether tolerance negates the efficacy of this nitrate in the long-term, a placebo-controlled study was performed in which ISMN was withdrawn briefly in a group of patients (n=16) who had received extended-release ISMN 60 to 120 mg once daily for 16 to 109 months. Blood pressure and wave reflection were determined by 24-hour ambulatory recorder and tonometer, respectively. During a 4-hour delay of the regular morning dose of ISMN, mean systolic blood pressure was higher than with the regular ISMN dosing schedule (P<0.0001). The maximum placebo-active difference was 16±4 mm Hg. The corresponding difference in augmentation index (a measure of pulse wave reflection) corrected for heart rate was 25±4% (P<0.001). The difference in pulse pressure was 13±3 mm Hg (P<0.001). There was no significant difference in diastolic blood pressure. For a subgroup (n=12) in which the effects of a single ISMN dose had been determined at the initiation of regular ISMN therapy, the mean change in augmentation index was of similar magnitude to that observed in their initial study. Thus, tolerance does not seriously diminish the antihypertensive efficacy of ISMN used as adjunct therapy in the chronic treatment of systolic hypertension. This agent lowers systolic blood pressure sufficiently to achieve therapeutic goal in some patients refractory to conventional treatment regimens.

Key Words: antihypertensive therapy • hypertension • arterial pressure • nitric oxide

This article has been cited by other articles:

				J. KARLSSON, A. PIVODIC, D. AGUIRRE, and T. J. SCHNITZER Efficacy, Safety, and Tolerability of the Cyclooxygenase-Inhibiting Nitric Oxide Donator Naproxcinod in Treating Osteoarthritis of the Hip or Knee J Rheumatol, June 1, 2009; 36(6): 1290 - 1297. [Abstract] [Full Text] [PDF]

				S. Steigerwalt Management of Hypertension in Diabetic Patients With Chronic Kidney Disease Diabetes Spectr, January 1, 2008; 21(1): 30 - 36. [Abstract] [Full Text] [PDF]

				S. M.L. Wallace, Yasmin, C. M. McEniery, K. M. Maki-Petaja, A. D. Booth, J. R. Cockcroft, and I. B. Wilkinson Isolated Systolic Hypertension Is Characterized by Increased Aortic Stiffness and Endothelial Dysfunction Hypertension, July 1, 2007; 50(1): 228 - 233. [Abstract] [Full Text] [PDF]

				S. D. Nesbitt Nitrates as Adjunct Hypertensive Treatment: A Possible Answer to Resistant Systolic Hypertension Hypertension, March 1, 2005; 45(3): 352 - 353. [Full Text] [PDF]